Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Standardization of drug names in the FDA Adverse Event Reporting System: The DiAna dictionary

View ORCID ProfileMichele Fusaroli, Valentina Giunchi, Vera Battini, Stefano Puligheddu, Charles Khouri, Carla Carnovale, Emanuel Raschi, Elisabetta Poluzzi
doi: https://doi.org/10.1101/2023.06.07.23291076
Michele Fusaroli
1Unit of Pharmacology, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Michele Fusaroli
  • For correspondence: michele.fusaroli2{at}unibo.it
Valentina Giunchi
1Unit of Pharmacology, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vera Battini
2Unit of Clinical Pharmacology, Department of Biomedical and Clinical Sciences (DIBIC), ASST Fatebenefratelli-Sacco University Hospital, Università degli Studi di Milano, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefano Puligheddu
1Unit of Pharmacology, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charles Khouri
3Grenoble Alpes University Hospital, Pharmacovigilance Unit, Grenoble, France
4Univ. Grenoble Alpes, HP2 Laboratory, Inserm U1300, Grenoble, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carla Carnovale
2Unit of Clinical Pharmacology, Department of Biomedical and Clinical Sciences (DIBIC), ASST Fatebenefratelli-Sacco University Hospital, Università degli Studi di Milano, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emanuel Raschi
1Unit of Pharmacology, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elisabetta Poluzzi
1Unit of Pharmacology, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Introduction The FDA Adverse Event Reporting System (FAERS) receives drug names in various forms, including brand names, active ingredients, abbreviations, and misspellings, which creates challenges in nomenclature standardization. The lack of consensus on standardization strategies and of transparency hampers replicability and accuracy in conducting disproportionality analysis using FAERS data.

Aim We have developed an open-source drug-to-ingredient dictionary called the DiAna dictionary (short for Disproportionality Analysis). Additionally, we have linked the DiAna dictionary to the WHO Anatomic Therapeutic Chemical (ATC) classification system.

Methods We retrieved all drug names reported to the FAERS from 2004 to December 2022. Using existing dictionaries such as RxNorm and string editing techniques, we automatically translated the drug names to active ingredients. Manual revision was performed to correct errors and improve translation accuracy. The resulting DiAna dictionary was linked to the ATC classification, proposing a primary ATC code for each ingredient.

Results We retrieved 18,151,842 reports, with 74,143,411 drug entries. We automatically translated and manually checked the first 14,832 terms, up to terms occurring at least 200 times (96.88% of total drug entries), to 6,282 unique active ingredients. Automatic unchecked translations extend the standardization to 346,854 terms (98.94%). After linking to the ATC classification, the most prominent drug classes in FAERS reports were immunomodulating (37.40%) and nervous system drugs (29.19%).

Conclusion We present the DiAna dictionary as an open-source tool and encourage experts to provide input and feedbacks. Regular updates can improve research quality and promote a common pharmacovigilance toolbox, ultimately advancing safety and improving study interpretability.

Key points

  • Drug name standardization impacts signal detection accuracy.

  • DiAna dictionary cleanses drugs in FAERS for improved data control.

  • DiAna’s transparency and flexibility improves interpretability.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study did not receive any funding

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data Availability

Availability of data and material: The dictionary and the linkage to the ATC classification are available at https://osf.io/zqu89/?view_only=237d052047c142cabd5d8ea2e765efc6. Code availability: All the processing, analyses, and visualization were obtained through R-software (version 4.2.1). The code for using the dictionary in the cleaning of the FAERS database is available at https://github.com/fusarolimichele/DiAna.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Back to top
PreviousNext
Posted June 12, 2023.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Standardization of drug names in the FDA Adverse Event Reporting System: The DiAna dictionary
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Standardization of drug names in the FDA Adverse Event Reporting System: The DiAna dictionary
Michele Fusaroli, Valentina Giunchi, Vera Battini, Stefano Puligheddu, Charles Khouri, Carla Carnovale, Emanuel Raschi, Elisabetta Poluzzi
medRxiv 2023.06.07.23291076; doi: https://doi.org/10.1101/2023.06.07.23291076
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Standardization of drug names in the FDA Adverse Event Reporting System: The DiAna dictionary
Michele Fusaroli, Valentina Giunchi, Vera Battini, Stefano Puligheddu, Charles Khouri, Carla Carnovale, Emanuel Raschi, Elisabetta Poluzzi
medRxiv 2023.06.07.23291076; doi: https://doi.org/10.1101/2023.06.07.23291076

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Pharmacology and Therapeutics
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)